May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Bevacizumab Binding to Human Sclera Post Topical Application
Author Affiliations & Notes
  • S. Beaton
    UPMC Eye Center, Pittsburgh, PA
  • J.Y. Yu
    UPMC Eye Center, Pittsburgh, PA
  • M.Y. Kahook
    UPMC Eye Center, Pittsburgh, PA
  • E. Guerriero
    UPMC Eye Center, Pittsburgh, PA
  • N. SundarRaj
    UPMC Eye Center, Pittsburgh, PA
  • J.S. Schuman
    UPMC Eye Center, Pittsburgh, PA
  • R.J. Noecker
    UPMC Eye Center, Pittsburgh, PA
  • Footnotes
    Commercial Relationships  S. Beaton, None; J.Y. Yu, None; M.Y. Kahook, None; E. Guerriero, None; N. SundarRaj, None; J.S. Schuman, None; R.J. Noecker, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 46. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Beaton, J.Y. Yu, M.Y. Kahook, E. Guerriero, N. SundarRaj, J.S. Schuman, R.J. Noecker; Bevacizumab Binding to Human Sclera Post Topical Application . Invest. Ophthalmol. Vis. Sci. 2006;47(13):46.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Bevacizumab (Avastin®, Genentech, California, USA), is an anti–angiogenesis medication used for cancer treatment and may have potential in modulating the fibrovascular response post trabeculectomy. This study will evaluate the amount of retained bevacizumab on scleral tissue after topical application.


Scleral bevacizumab concentrations were determined using an enzyme–linked immunosorbent assay (ELISA) with the wells coated with avidin. Biotinylated bevacizumab was used as the primary antibody. Goat anti–human IgG conjugated to horseradish peroxidase was utilized as the secondary antibody. Four concentrations of biotinylated bevacizumab (1.25 mg, 0.6 mg, 0.3 mg and 0.125 mg per 0.05ml) were used as standards . The supernatant of human scleral tissue was treated with the biotinylated bevacizumab for 30 minutes prior to performing the ELISA. The concentration of each supernatant tissue group was compared to the standard curves to calculate the amount of bevacizumab scleral binding.


The concentration of retained bevacizumab in the treated scleral tissue are shown below:  


Bevacizumab is retained, dependent on dose, in scleral tissue after topical application and may have a role in treating fibrovascular diseases of the ocular surface and inhibiting fibroblast proliferation following surgery. Further studies are needed to better delineate optimal delivery technique and dosing.

Keywords: sclera • wound healing 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.